UNSPSC 51341502: Fosamprenavir

This classification denotes a protease inhibitor with the molecular formula C25H36N3O9PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WOU1621EEG, chemically known as carbamic acid, ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, c-((3s)-tetrahydro-3-furanyl) ester but generally known as fosamprenavir, which bears US NIH Compound Identifier 131536.

UNSPSC 51341502 Fosamprenavir is a Commodity code that nominally covers a specific antiretroviral pharmaceutical product, yet recent state and local opportunities tagged to this code show minimal alignment with its stated scope. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium in August 2026 for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), and Seminole County, Florida posted an IFB in June 2026 for Naloxone and safe drug deactivation systems. Neither opportunity involves fosamprenavir procurement; the code shows little relevant recent activity under its actual product definition.

State and local issuing bodies applying this code appear to be using it as a catch-all for pharmaceutical and health-supply purchases rather than for fosamprenavir specifically. The Illinois procurement was a completed IFB award to Chartwell Rx LLC valued at $2,999,999.11 over the contract life, while the Seminole County opportunity sought annual volumes of 1,900 units of Naloxone and 800 deactivation systems with a two-year initial term and one-year renewal option. Both procurements were handled by state and county health-related bodies and included standard compliance requirements such as drug-free workplace certification and E-Verify. Geographic activity appears concentrated in the Midwest and Southeast, though the sample is too small to establish a meaningful pattern. Business development professionals should note that this code's recent activity does not reflect fosamprenavir-specific demand; opportunities tagged here may require verification against actual product scope before pursing.